Incretin hormones and the satiation signal

International Journal of Obesity

Volumn 37, Issue 9, 2013, Pages 1161-1168

  Holst, J J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Exenatide; glucagon like peptide 1; incretin; liraglutide

Indexed keywords

EXENDIN 4; EXENDIN 9-39; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

BARIATRIC SURGERY; DRUG APPROVAL; DRUG HALF LIFE; FOOD INTAKE; HUMAN; HYPERGLYCEMIA; INHIBITION KINETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SATIETY; WEIGHT REDUCTION;

ANIMALS; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; OBESITY; PEPTIDES; RECEPTORS, GLUCAGON; SATIATION; SIGNAL TRANSDUCTION; VENOMS; WEIGHT LOSS;

EID: 84883754628     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2012.208     Document Type: Review

References (132)

1. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115-121. (Pubitemid 36773875)
2. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-Like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 2008; 14: 161-168.
3. Holst JJ. The physiology of glucagon-Like peptide 1. Physiol Rev 2007; 87: 1409-1439. (Pubitemid 350041474)
4. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
5. Drucker DJ, Nauck MA. The incretin system: Glucagon-Like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type diabetes. Lancet 2006; 368: 1696-1705. (Pubitemid 46048557)
6. Holst JJ. The physiology of glucagon-Like peptide 1. Physiol Rev 2007; 87: 1409-1439. (Pubitemid 350041474)
7. Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin based therapies for type diabetes: Incretin mimetics and DPP-4 inhibitors. Cur Diabetes Rev 2008; 4: 101-109.
8. Edholm T, Degerblad M, Gryback P, Hilsted L, Holst JJ, Jacobsson H et al. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-Glucose homeostasis. Neurogastroenterol Motil 2010; 22: 1191-1201.
9. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742. (Pubitemid 34778728)
10. Ugleholdt R, Pedersen J, Bassi MR, Fuchtbauer EM, Jorgensen SM, Kissow HL et al. Transgenic rescue of adipocyte glucose-Dependent insulinotropic polypeptide receptor expression restores high fat diet-Induced body weight gain. J Biol Chem 2011; 286: 44632-44645.
11. Asmar M, Tangaa W, Madsbad S, Hare K, Astrup A, Flint A et al. On the role of glucose-Dependent insulintropic polypeptide in postprandial metabolism in humans. Am J Physiol Endocrinol Metab 2010; 298: E614-E621.
12. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7: 2294-2300.
13. Schick RR, vorm Walde T, Zimmermann JP, Schusdziarra V, Classen M. Glucagonlike peptide 1-A novel brain peptide involved in feeding regulation. In: Ditschuneit H, Gries FA, Hauner H, Schusdziarra V, Wechsler JG (eds.) Obesity in Europe 1993. John Libbey & Co.Ltd, 1994, pp 363-367.
14. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-Like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72. (Pubitemid 26008136)
15. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271(Pt 2): R848-R856.
16. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-Like peptide-1 and other preproglucagon-Derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997; 77: 257-270. (Pubitemid 27060323)
17. Burcelin R, Cani PD, Knauf C. Glucagon-Like peptide-1 and energy homeostasis. J Nutr 2007; 137(11 Suppl): 2534S-2538S. (Pubitemid 350058731)
18. Shimizu I, Hirota M, Ohboshi C, Shima K. Identification and localization of glucagon-Like peptide-1 and its receptor in rat brain. Endocrinology 1987; 121: 1076-1082. (Pubitemid 17139162)
19. Ranganath LR. The entero-Insular axis: Implications for human metabolism. Clin Chem Lab Med 2008; 46: 43-56.
20. Mora F, Exposito I, Sanz B, Blazquez E. Selective release of glutamine and glutamic acid produced by perfusion of GLP-1 (7-36) amide in the basal ganglia of the conscious rat. Brain Res Bull 1992; 29: 359-361.
21. Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005; 92: 798-806. (Pubitemid 40229551)
22. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to cntrol for food intake. Endocrinology 2011; 153: 647-658.
23. Dossat AM, Lilly N, Kay K, Williams DL. Glucagon-Like peptide receptors in nucleus accumbens affect food intake. J Neurosci 2011; 31: 14453-14457.
24. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP. The glucagon-Like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: A new role for mesolimbic GLP-1 receptors. J Neurosci 2012; 32: 4812-4820.
25. Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1187-1209. (Pubitemid 44874228)
26. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-Like peptide-1 (GLP-1) with the blood-Brain barrier. J Mol Neurosci 2002; 18: 7-14. (Pubitemid 34252619)
27. Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides. Prog Neurobiol 2010; 92: 442-462.
28. Vrang N, Phifer CB, Corkern MM, Berthoud HR. Gastric distension induces c-Fos in medullary GLP-1/2-Containing neurons. Am J Physiol Regul Integr Comp Physiol 2003; 285: R470-R478. (Pubitemid 36898916)
29. Rinaman L. Interoceptive stress activates glucagon-Like peptide-1 neurons that project to the hypothalamus. Am J Physiol 1999; 277(Pt 2): R582-R590. (Pubitemid 29415130)
30. Rinaman L. A functional role for central glucagon-Like peptide-1 receptors in lithium chloride-Induced anorexia. Am J Physiol 1999; 277(Pt 2): R1537-R1540.
31. Lachey JL, D'Alessio DA, Rinaman L, Elmquist JK, Drucker DJ, Seeley RJ. The role of central GLP-1 in mediating the effects of visceral illness: Differential effects in rats and mice. Endocrinology 2005; 146: 458-462. (Pubitemid 40051771)
32. Barrera JG, Jones KR, Herman JP, D'Alessio DA, Woods SC, Seeley RJ. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagonlike peptide-1 loss of function. J Neurosci 2011; 31: 3904-3913.
33. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011; 152: 3103-3112.
34. Hisadome K, Reimann F, Gribble FM, Trapp S. Leptin directly depolarizes preproglucagon neurons in the nucleus tractus solitarius: Electrical properties of glucagon-Like Peptide neurons. Diabetes 2010; 59: 1890-1898.
35. Holmes GM, Browning KN, Tong M, Qualls-Creekmore E, Travagli RA. Vagally mediated effects of glucagon-Like peptide 1: In vitro and in vivo gastric actions. J Physiol 2009; 587(Pt 19): 4749-4759.
36. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-Like Peptide Promotes Satiety and Suppresses Energy Intake in Humans. J Clin Invest 1998; 101: 515-520. (Pubitemid 28084232)
37. Gutzwiller JP, ke B, Drewe J, Hildebrand P, Ketterer S, Handschin D et al. Glucagon-Like peptide-1: A potent regulator of food intake in humans. Gut 1999; 44: 81-86. (Pubitemid 29143284)
38. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J et al. Glucagon-Like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276(Pt 2): R1541-R1544. (Pubitemid 29249681)
39. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM et al. A meta-Analysis of the effect of glucagon-Like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-4389. (Pubitemid 32848563)
40. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME et al. Safety, tolerability and sustained weight loss over years with the once-Daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36: 843-854.
41. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagonlike peptide-1 plays a physiological role in satiety. Endocrinology 2009; 150: 1680-1687.
42. Patterson JT, Ottaway N, Gelfanov VM, Smiley DL, Perez-Tilve D, Pfluger PT et al. A novel human-Based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chem Biol 2011; 6: 135-145.
43. Le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A et al. Gut hormones as mediators of appetite and weight loss after Roux-En-Y gastric bypass. Ann Surg 2007; 246: 780-785. (Pubitemid 350035654)
44. Bowen J, Noakes M, Clifton PM. Appetite regulatory hormone responses to various dietary proteins differ by body mass index status despite similar reductions in ad libitum energy intake. J Clin Endocrinol Metab 2006; 91: 2913-2919. (Pubitemid 44271735)
45. Lodefalk M, Carlsson-Skwirut C, Holst JJ, Aman J, Bang P. Effects of fat supplementation on postprandial GIP, GLP-1, ghrelin and IGFBP-1 levels: A pilot study on adolescents with type diabetes. Horm Res Paediatr 2010; 73: 355-362.
46. Frost GS, Brynes AE, Dhillo WS, Bloom SR, McBurney MI. The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal. Eur J Clin Nutr 2003; 57: 293-298. (Pubitemid 36240482)
47. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type and type diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 2706-2713. (Pubitemid 36724446)
48. Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O, Beck-Nielsen H. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J Obes 1983; 7: 529-538. (Pubitemid 14239953)
49. Verdich C, Toubro S, Buemann B, Lysgard MJ, Juul HJ, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-Induced satiety-Effect of obesity and weight reduction. Int J Obes 2001; 25: 1206-1214. (Pubitemid 32721544)
50. Tomasik P, Sztefko K, Starzyk J. Entero-Insular axis in children with simple obesity. Pediatr Endocrinol Diabetes Metab 2009; 15: 63-69.
51. Chanoine JP, Mackelvie KJ, Barr SI, Wong AC, Meneilly GS, Elahi DH. GLP-1 and appetite responses to a meal in lean and overweight adolescents following exercise. Obesity (Silver Spring) 2008; 16: 202-204. (Pubitemid 351271973)
52. Carr RD, Larsen MO, Jelic K, Lindgren O, Vikman J, Holst JJ et al. Secretion and dipeptidyl peptidase-4-Mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 2010; 95: 872-878.
53. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK et al. Determinants of the impaired secretion of glucagon-Like peptide-1 in type diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723. (Pubitemid 32755966)
54. Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type diabetic patients. Diabetes 2008; 57: 1340-1348.
55. Naslund E, Gryback P, Backman L, Jacobsson H, Holst JJ, Theodorsson E et al. Distal small bowel hormones: Correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998; 43: 945-952. (Pubitemid 28211450)
56. Rask E, Olsson T, Soderberg S, Johnson O, Seckl J, Holst JJ et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001; 24: 1640-1645. (Pubitemid 33716463)
57. Aoki K, Miyazaki T, Nagakura J, Orime K, Togashi Y, Terauchi Y. Effects of premeal versus post-Meal administration of miglitol on plasma glucagon-Like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men. Endocr J 2010; 57: 673-677.
58. Diakogiannaki E, Gribble FM, Reimann F. Nutrient detection by incretin hormone secreting cells. Physiol Behav 2012; 106: 387-393.
59. Ahren B, Holst JJ. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 2001; 50: 1030-1038. (Pubitemid 32374533)
60. Ueda SY, Yoshikawa T, Katsura Y, Usui T, Fujimoto S. Comparable effects of moderate intensity exercise on changes in anorectic gut hormone levels and energy intake to high intensity exercise. J Endocrinol 2009; 203: 357-364.
61. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-Like peptide-1 and blunted glucose-Dependent insulinotropic peptide secretion are associated with Roux-En-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007; 3: 597-601. (Pubitemid 350091417)
62. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A et al. Gut hormones as mediators of appetite and weight loss after Roux-En-Y gastric bypass. Ann Surg 2007; 246: 780-785. (Pubitemid 350035654)
63. Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL et al. Glucagon-Like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006; 91: 1735-1740.
64. Naslund E, Backman L, Holst JJ, Theodorsson E, Hellstrom PM. Importance of small bowel peptides for the improved glucose metabolism years after jejunoileal bypass for obesity. Obes Surg 1998; 8: 253-260. (Pubitemid 28334120)
65. Falken Y, Hellstrom PM, Holst JJ, Naslund E. Changes in glucose homeostasis after Roux-En-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: Role of gut peptides. J Clin Endocrinol Metab 2011; 96: 2227-2235.
66. Alam ML, Van Der Schueren BJ, Ahren B, Wang GC, Swerdlow NJ, Arias S et al. Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type diabetes. Diabetes Obes Metab 2011; 13: 378-381.
67. Lim GE, Huang GJ, Flora N, LeRoith D, Rhodes CJ, Brubaker PL. Insulin regulates glucagon-Like peptide-1 secretion from the enteroendocrine L cell. Endocrinology 2009; 150: 580-591.
68. Pournaras DJ, Osborne A, Hawkins SC, Vincent RP, Mahon D, Ewings P et al. Remission of type diabetes after gastric bypass and banding: Mechanisms and year outcomes. Ann Surg 2010; 252: 966-971.
69. Knop FK. Resolution of type diabetes following gastric bypass surgery: Involvement of gut-Derived glucagon and glucagonotropic signalling' Diabetologia 2009; 52: 2270-2276.
70. Scheen AJ, De FJ, De RA, Paquot N. Bariatric surgery in patients with type diabetes: Benefits, risks, indications and perspectives. Diabetes Metab 2009; 35(Pt 2): 537-543.
71. Dirksen C, Hansen DL, Madsbad S, Hvolris LE, Naver LS, Holst JJ et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: A case report. Diabetes Care 2010; 33: 375-377.
72. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagonlike peptide 1-Stimulated postprandial insulin secretion in humans. Diabetes 2011; 60: 2308-2314.
73. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-Like peptide-1-(7-36)amide is transformed to glucagon-Like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine [In Process Citation]. Endocrinology 1999; 140: 5356-5363.
74. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-Like peptide undergoes differential tissue-Specific metabolism in the anesthetized pig. Am J Physiol 1996; 271(Pt 1): E458-E464.
75. Wettergren A, Pridal L, Wojdemann M, Holst JJ. Amidated and nonamidated glucagon-Like peptide-1 (GLP-1): Non-Pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regul Pept 1998; 77: 83-87. (Pubitemid 28467092)
76. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-Like peptide in type diabetic patients. Diabetes 2001; 50: 609-613. (Pubitemid 32195226)
77. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE et al. Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed {beta}-Cell Function in Patients with Type Diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894. (Pubitemid 41159387)
78. Deacon CF, Carr RD, Holst JJ. DPP-4 inhibitor therapy: New directions in the treatment of type diabetes. Front Biosci 2008; 13: 1780-1794. (Pubitemid 351599732)
79. Williams DL. Minireview: Finding the sweet spot: Peripheral versus central glucagon-Like peptide action in feeding and glucose homeostasis. Endocrinology 2009; 150: 2997-3001.
80. Holst JJ, Deacon CF. Glucagon-Like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005; 48: 612-615. (Pubitemid 40591213)
81. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD et al. Glucagonlike peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007; 148: 4965-4973. (Pubitemid 47481523)
82. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S et al. Receptor gene expression of glucagon-Like peptide-1, but not glucose-Dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004; 110: 36-43. (Pubitemid 38180536)
83. Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ et al. Receptor-Mediated activation of gastric vagal afferents by glucagon-Like peptide in the rat. Neurogastroenterol Motil 2009; 21: 978-E78.
84. Baumgartner I, Pacheco-Lopez G, Ruttimann EB, Arnold M, Asarian L, Langhans W et al. Hepatic-Portal vein infusions of glucagon-Like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats. J Neuroendocrinol 2010; 22: 557-563.
85. Grill HJ, Hayes MR. The nucleus tractus solitarius: A portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake. Int J Obes (Lond) 2009; 33(Suppl 1): S11-S15.
86. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagonlike peptide receptors regulate glucose homeostasis but not food intake. Diabetes 2008; 57: 2046-2054.
87. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996; 271(Pt 1): E808-E813.
88. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagonlike peptide-1 on food intake are attenuated by ablation of the vagal-Brainstemhypothalamic pathway. Brain Res 2005; 1044: 127-131. (Pubitemid 40616060)
89. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-Like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009; 150: 1174-1181.
90. Hayes MR, Kanoski SE, De Jonghe BC, Leichner TM, Alhadeff AL, Fortin SM et al. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-Like-Peptide-1. Am J Physiol Regul Integr Comp Physiol 2011; 301: R1479-R1485.
91. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-Like peptide-1 inhibits gastric emptying via vagal afferent-Mediated central mechanisms. Am J Physiol 1997; 273(Pt 1): G920-G927.
92. Wettergren A, Wojdemann M, Holst JJ. Glucagon-Like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275(Pt 1): G984-G992.
93. Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-Like peptide-1 7-36 amide and peptide YY from the L-Cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 1994; 29: 501-505.
94. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-Like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997; 40: 597-601. (Pubitemid 27278325)
95. Pannacciulli N, Le DS, Salbe AD, Chen K, Reiman EM, Tataranni PA et al. Postprandial glucagon-Like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage 2007; 35: 511-517. (Pubitemid 46400565)
96. Van Dijk G, Thiele TE. Glucagon-Like peptide-1 (7-36) amide: A central regulator of satiety and interoceptive stress. Neuropeptides 1999; 33: 406-414. (Pubitemid 29530133)
97. Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-Like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagonlike peptide I. Diabetes 1996; 45: 832-835. (Pubitemid 26168585)
98. Baraboi ED, Smith P, Ferguson AV, Richard D. Lesions of area postrema and subfornical organ alter exendin-4-Induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1098-R1110.
99. Plamboeck A, Veedfald S, Deacon C, Wettergren A, Svendsen L, Meisner S et al. The effect of GLP-1 on fod intake is lost in Truncal vagotomized subjects. Diabetes 2012; 61(Suppl 1): A475.
100. Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 2010; 57: 359-372.
101. Rinaman L. Interoceptive stress activates glucagon-Like peptide-1 neurons that project to the hypothalamus. Am J Physiol 1999; 277(Pt 2): R582-R590. (Pubitemid 29415130)
102. Raun K, Jelsing J, Vrang N, Tang-Christensen M, Dahl K, Knudsen LB. The GLP-1 analog liraglutide activates brainstem and hypothalamic neurons involved in appetite regulation. Diabetes 2010; 59(Suppl 1): A159-A160.
103. Tesauro M, Schinzari F, Caramanti M, Lauro R, Cardillo C. Cardiovascular and metabolic effects of ghrelin. Curr Diabetes Rev 2010; 6: 228-235.
104. Rogers RC, Hermann GE. Mechanisms of action of CCK to activate central vagal afferent terminals. Peptides 2008; 29: 1716-1725.
105. Riediger T, Eisele N, Scheel C, Lutz TA. Effects of glucagon-Like and oxyntomodulin on neuronal activity of ghrelin-Sensitive neurons in the hypothalamic arcuate nucleus. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1061-R1067.
106. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009; 122(Suppl): S3-S10.
107. McGill JB. Impact of incretin therapy on islet dysfunction: An underlying defect in the pathophysiology of type diabetes. Postgrad Med 2009; 121: 46-58.
108. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-Acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202. (Pubitemid 34208381)
109. Kim D, Macconell L, Zhuang D, Kothare PA, Trautmann M, Fineman M et al. Effects of once-Weekly dosing of a long-Acting release formulation of exenatide on glucose control and body weight in subjects with type diabetes. Diabetes Care 2007; 30: 1487-1493. (Pubitemid 46871159)
110. Monami M, Marchionni N, Mannucci E. Glucagon-Like peptide-1 receptor agonists in type diabetes: A meta-Analysis of randomized clinical trials. Eur J Endocrinol 2009; 160: 909-917.
111. Norris SL, Lee N, Thakurta S, Chan BKS. Exenatide efficacy and safety: A systematic review. Diabet Med 2009; 26: 837-846.
112. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, During M et al. Weight loss with liraglutide, a once-Daily human glucagon-Like peptide-1 analogue for type diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11: 1163-1172.
113. Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: Efficacy and weight benefits. Postgrad Med 2009; 121: 5-15.
114. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP et al. Liraglutide, a long-Acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type diabetes mellitus. Diabetes Care 2007; 30: 1608-1610. (Pubitemid 46871185)
115. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
116. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH et al. Liraglutide once a day versus exenatide twice a day for type diabetes: A 26-Week randomised, parallel-Group, multinational, open-Label trial (LEAD-6). Lancet 2009; 374: 39-47.
117. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A et al. Short-Term effects of liraglutide on visceral fat adiposity, appetite, and food preference: A pilot study of obese Japanese patients with type diabetes. Cardiovasc Diabetol 2011; 10: 109.
118. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al. Effects of liraglutide in the treatment of obesity: A randomised, double-Blind, placebocontrolled study. Lancet 2009; 374: 1606-1616.
119. Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM et al. Exenatide as a weight-Loss therapy in extreme pediatric obesity: A randomized, controlled pilot study. Obesity 2012; 20: 364-370.
120. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes. Diabetes Care 2010; 33: 1173-1175.
121. Pinelli NR, Jantz A, Smith Z, Abouhassan A, Ayar C, Jaber NA et al. Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers. J Clin Pharmacol 2011; 51: 165-172.
122. Horowitz M, Flint A, Doran S, Rasmussen MF, Kapitza C, Andreasen AH et al. Effects of the once-Daily human GLP-1 analogue liraglutide on appetite and energy intake in type diabetes. Diabetologia 2008; 51(Suppl 1): S355.
123. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type diabetes. Regul Pept 2008; 151: 123-129.
124. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J et al. Bedtime administration of NN2211, a long-Acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type diabetes. Diabetes 2002; 51: 424-429. (Pubitemid 34764798)
125. Jelsing J, Vrang N, Hansen G, Ravn K, Tang-Christensen M, Knudsen LB. Liraglutide: Short lived effect on gastric emptying-Long lasting effects on bodyweight. Diabetes Obes Metab 2012; 14: 531-538.
126. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-Like peptide-1 inhibits gastric emptying via vagal afferent-Mediated central mechanisms. Am J Physiol 1997; 273(Pt 1): G920-G927.
127. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over weeks in sulfonylurea-Treated patients with type diabetes. Diabetes Care 2004; 27: 2628-2635. (Pubitemid 39441462)
128. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over weeks in metformin-Treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100. (Pubitemid 40616618)
129. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a once-Daily human GLP-1 analogue, provides sustained improvements in glycaemic control and weight for two years as monotherapy compared with glimepiride in patients with type Diabetes. Obes Metab, 2010, 13: 348-356
130. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type diabetes mellitus: A randomised controlled trial (LEAD-5 met'SU). Diabetologia 2009, 52:2046-2055.
131. Zinman B, Hoogwerf BJ, Duran GS, Milton DR, Giaconia JM, Kim DD et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type diabetes: A randomized trial. Ann Intern Med 2007;146: 477-485. (Pubitemid 351650556)
132. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type diabetes: An overview of the LEAD 1-5 studies Diabetes Obes Metab 2009 11(Suppl 3) 26-34